OBI Pharma (ROCO:4174) Piotroski F-Score: 3 (As of Jul. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
43 GF Score
Price NT$28.40
GF Value NT$138.61
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma Piotroski F-Score?

OBI Pharma ROCO:4174 -1.90% 43 Piotroski F-Score is 3 as of Jul. 15, 2026, which is at its 10-year median of 3.00. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.61 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,333 Biotechnology companies, OBI Pharma ranks better than 54.69% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OBI Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for OBI Pharma's Piotroski F-Score or its related term are showing as below:

ROCO:4174' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 6
Current: 3

During the past 13 years, the highest Piotroski F-Score of OBI Pharma was 6. The lowest was 1. And the median was 3.

OBI Pharma  (ROCO:4174) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OBI Pharma Piotroski F-Score Related Terms


OBI Pharma Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for OBI Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma Piotroski F-Score Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 4.00 3.00 3.00

OBI Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

ROCO:4174 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, OBI Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Piotroski F-Score falls into.


ROCO:4174
43GF Score
OBI Pharma Inc ROCO:4174
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -511.545 + -653.498 + -468.319 + -419.461 = NT$-2,052.82 Mil.
Cash Flow from Operations was -662.742 + -470.714 + -407.426 + -479.252 = NT$-2,020.13 Mil.
Revenue was 14.458 + 12.758 + 10.522 + 20.837 = NT$58.58 Mil.
Gross Profit was -16.183 + -23.226 + -22.263 + -15.857 = NT$-77.53 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(5653.692 + 4894.084 + 4323.423 + 3829.208 + 3421.265) / 5 = NT$4424.3344 Mil.
Total Assets at the begining of this year (Dec24) was NT$5,653.69 Mil.
Long-Term Debt & Capital Lease Obligation was NT$339.44 Mil.
Total Current Assets was NT$1,580.09 Mil.
Total Current Liabilities was NT$350.56 Mil.
Net Income was -522.255 + -540.661 + -519.288 + -727.822 = NT$-2,310.03 Mil.

Revenue was 9.135 + 19.016 + 22.979 + 11.548 = NT$62.68 Mil.
Gross Profit was -26.167 + -13.921 + -15.079 + -21.107 = NT$-76.27 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(5611.114 + 5035.251 + 4526.332 + 3998.993 + 5653.692) / 5 = NT$4965.0764 Mil.
Total Assets at the begining of last year (Dec23) was NT$5,611.11 Mil.
Long-Term Debt & Capital Lease Obligation was NT$415.01 Mil.
Total Current Assets was NT$3,439.78 Mil.
Total Current Liabilities was NT$412.37 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OBI Pharma's current Net Income (TTM) was -2,052.82. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OBI Pharma's current Cash Flow from Operations (TTM) was -2,020.13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-2052.823/5653.692
=-0.36309424

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-2310.026/5611.114
=-0.41168759

OBI Pharma's return on assets of this year was -0.36309424. OBI Pharma's return on assets of last year was -0.41168759. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OBI Pharma's current Net Income (TTM) was -2,052.82. OBI Pharma's current Cash Flow from Operations (TTM) was -2,020.13. ==> -2,020.13 > -2,052.82 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=339.437/4424.3344
=0.07672047

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=415.007/4965.0764
=0.08358522

OBI Pharma's gearing of this year was 0.07672047. OBI Pharma's gearing of last year was 0.08358522. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1580.085/350.557
=4.50735544

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=3439.783/412.37
=8.34149671

OBI Pharma's current ratio of this year was 4.50735544. OBI Pharma's current ratio of last year was 8.34149671. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OBI Pharma's number of shares in issue this year was 131.58. OBI Pharma's number of shares in issue last year was 131.484. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-77.529/58.575
=-1.32358515

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-76.274/62.678
=-1.21691822

OBI Pharma's gross margin of this year was -1.32358515. OBI Pharma's gross margin of last year was -1.21691822. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=58.575/5653.692
=0.01036049

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=62.678/5611.114
=0.01117033

OBI Pharma's asset turnover of this year was 0.01036049. OBI Pharma's asset turnover of last year was 0.01117033. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OBI Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
OBI Pharma (ROCO:4174) has a Piotroski F-Score of 3 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OBI Pharma and its competitors. This is near median its historical median of 3.00. Over the past decade, OBI Pharma's Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, OBI Pharma ranks #604 out of 1333 companies in the Biotechnology industry, placing it in the top 45.3%.
Is OBI Pharma's Piotroski F-Score too high?
OBI Pharma's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. OBI Pharma's value of 3 is 0% at this industry median. Based on the distribution chart, OBI Pharma ranks #604 out of 1333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #604 out of 1333 companies for Piotroski F-Score. This puts OBI Pharma in the upper half of its industry. The industry median Piotroski F-Score is 3.00. OBI Pharma's value of 3 is 0% at this benchmark. Historically, OBI Pharma's own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, OBI Pharma has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OBI Pharma's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OBI Pharma and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OBI Pharma's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$28.40 — trading 79.5% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Piotroski F-Score is 3 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$28.40 is trading 79.5% below its estimated GF Value™ of NT$138.61. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: NT$138.61 vs. price of NT$28.40 (79.5% below fair value)
  • GF Score™: 43/100 with 9 warning signs
  • Industry Position: 0% at the Biotechnology median (#604 of 1333)

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score

Get the complete analysis for ROCO:4174

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.40
Price
NT$138.61
GF Value